Featured Clinical Trials Supported by the National Cancer Institute
Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.
To find other cancer trials open to enrollment:
- Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the clinical trials search form to look online for trials listed on NCI's Cancer.gov website. The form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
(Posted: 07/10/2012) - In this pilot study, men diagnosed with or suspected of having low-risk prostate cancer will undergo advanced MRI techniques to guide a biopsy to the tumor area; subsequently, they will be treated using MRI-guided focal laser ablation therapy to only that area of the prostate.
Trastuzumab for Women with HER2-Low Breast Cancer
(Posted: 06/26/2012) - In this clinical trial, women who have recently undergone surgical resection for HER2-low breast cancer and are at high risk for recurrence will undergo adjuvant chemotherapy and be randomly assigned to 1 year of trastuzumab treatment or no trastuzumab.
Adjuvant Everolimus for Resected Kidney Cancer
(Posted: 06/12/2012) - In this clinical trial, patients with renal cell cancer who have undergone partial or complete nephrectomy will be randomly assigned to take everolimus tablets or matching placebo tablets daily for 54 weeks.
Combining Angiogenesis-Targeted Treatments for Liver Cancer
(Posted: 05/29/2012) - In this trial, patients with unresectable hepatocellular carcinoma who are ineligible for a liver transplant or other local therapies will be given oral sorafenib at the standard approved dose and intravenous TRC105.
Experimental Antibody for Treatment-Resistant Liver Cancer
(Posted: 05/15/2012) - In this trial, patients with unresectable hepatocellular carcinoma who are ineligible for liver transplants or other localized therapies, and who did not benefit from or could not tolerate treatment with sorafenib, will be treated with intravenous TRC105 every 2 weeks.